This inventor holds 1 USPTO granted patent. Top assignee: Myriad Genetics, Inc.. Active years: 2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007
Title: **Innovative Contributions of Fabiana Filigheddu in Genetic Research**
Introduction
Fabiana Filigheddu is a distinguished inventor based in Sassari, Italy. With a keen focus on pharmaceutical genomics, she has made significant contributions in understanding how genetic variations impact drug responses. Her innovative work addresses the nuances of antihypertensive treatments through genetic insights.
Latest Patents
Filigheddu holds a patent for a groundbreaking invention titled "Drug response marker in beta-1 adrenergic receptor gene." This patent presents methods for utilizing a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker. Specifically, it identifies the presence of the A145G genetic variation, which is pivotal in predicting how individuals respond to different antihypertensive drugs. This innovation not only optimizes treatment protocols for patients but also aids in selecting suitable candidates for clinical trials involving antihypertensive drugs.
Career Highlights
Fabiana is a valuable member of Myriad Genetics, Inc., where she leverages her expertise to advance genetic research and improve patient care. Her work has been crucial in bridging the gap between genetics and pharmacology, thereby enhancing therapeutic outcomes.
Collaborations
Throughout her career, Fabiana has collaborated with notable professionals in the field, including her coworkers Julia Reid and Susanne Wagner. These collaborations have enriched her research and contributed to the overall advancement of genetic applications in medicine.
Conclusion
Fabiana Filigheddu stands out as an innovator whose contributions to genetic research are shaping the future of personalized medicine. Her patented work exemplifies the importance of genetic markers in optimizing treatment strategies, paving the way for more effective healthcare solutions. The impact of her innovations will continue to resonate in both academic and clinical settings, fostering a deeper understanding of the interplay between genetics and medication responses.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile